 |
217 Diseases |  |
230 Trials |
|
230 Trials |  |
3979 News |  |
| «12...3738394041424344454647...5051» |
- ||| Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - May 4, 2017
P2, N=1460, Recruiting, Sponsor: UNICANCER
N=460 --> 1460 | Trial primary completion date: Oct 2016 --> Jun 2019
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - May 4, 2017
P3, N=328, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=460 --> 1460 | Trial primary completion date: Oct 2016 --> Jun 2019 Recruiting --> Active, not recruiting
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial primary completion date, Metastases: TavIx: Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (clinicaltrials.gov) - May 4, 2017
P3, N=762, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Jun 2017
- | Herceptin (trastuzumab) / Roche
New P2 trial: TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer (clinicaltrials.gov) - May 4, 2017
P2, N=70, Recruiting, Sponsor: Guangdong General Hospital
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial primary completion date: NeoPAL: Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women (clinicaltrials.gov) - May 3, 2017
P2, N=125, Active, not recruiting, Sponsor: UNICANCER
Trial primary completion date: Jun 2014 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Jan 2018
- | epirubicin / Generic mfg.
Journal: Intensity modulated radiation therapy to treat primary female mediastinal seminoma and massive pericardial effusion: A case report. (Pubmed Central) - May 1, 2017
Following radiotherapy, the patient was considered to have a complete response to the treatment, and subsequent to a 5-year follow-up, no recurrence or metastasis was identified. To the best of our knowledge, no similar cases have been reported in the literature at present.
- Vectibix (panitumumab) / Amgen
Trial primary completion date: Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer (clinicaltrials.gov) - Apr 28, 2017
P2, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
To the best of our knowledge, no similar cases have been reported in the literature at present. Trial primary completion date: Nov 2017 --> Nov 2018
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: APHINITY: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (clinicaltrials.gov) - Apr 21, 2017
P3, N=4805, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2017 --> Nov 2018 Trial primary completion date: Dec 2023 --> Dec 2016
- | pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg.
New P4 trial, Head-to-Head: ESNDBCP: Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients (clinicaltrials.gov) - Apr 20, 2017
P4, N=384, Recruiting, Sponsor: Zhejiang University
- | Enrollment closed: CBCSG010: Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer (clinicaltrials.gov) - Apr 19, 2017
P3, N=636, Active, not recruiting, Sponsor: China Breast Cancer Clinical Study Group
Trial primary completion date: Dec 2023 --> Dec 2016 Recruiting --> Active, not recruiting
- | Trial primary completion date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Apr 7, 2017
P2/3, N=60, Recruiting, Sponsor: Dr. Gordon Buduhan
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Feb 2018
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Apr 4, 2017
P2, N=40, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial primary completion date: Feb 2017 --> Feb 2018 Trial primary completion date: Jul 2018 --> Jul 2019
- | Trial primary completion date, Metastases: SEED: Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma (clinicaltrials.gov) - Mar 27, 2017
P2, N=98, Recruiting, Sponsor: Rigshospitalet, Denmark
Trial primary completion date: Jul 2018 --> Jul 2019 Trial primary completion date: Jun 2017 --> Jun 2019
- | Farydak (panobinostat) / Secura Bio
Trial completion, Trial initiation date, Metastases: Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors (clinicaltrials.gov) - Mar 24, 2017
P1, N=40, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Jun 2017 --> Jun 2019 Active, not recruiting --> Completed | Initiation date: Jun 2009 --> Sep 2009
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov) - Mar 16, 2017
P3, N=855, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | Initiation date: Jun 2009 --> Sep 2009 Not yet recruiting --> Recruiting
- | Trial completion, BRCA Biomarker: BERNAQ: Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer (clinicaltrials.gov) - Mar 13, 2017
P2, N=30, Completed, Sponsor: Fundaci
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - Mar 9, 2017
P3, N=328, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Sep 2023 --> Apr 2022
- | Trial primary completion date, Metastases: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Mar 7, 2017
P2/3, N=716, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Sep 2023 --> Apr 2022 Trial primary completion date: Dec 2016 --> Jun 2017
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Feb 27, 2017
P3, N=1846, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Feb 2018 --> Jan 2024
- | goserelin acetate / Generic mfg., epirubicin / Generic mfg.
Enrollment open: Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer (clinicaltrials.gov) - Feb 27, 2017
P3, N=234, Recruiting, Sponsor: Peking University
Trial primary completion date: Feb 2018 --> Jan 2024 Not yet recruiting --> Recruiting
- |||| Prolia (denosumab) / Amgen
Enrollment open, Trial initiation date, Trial primary completion date: Denosumab as an add-on Neoadjuvant Treatment (GeparX) (clinicaltrials.gov) - Feb 23, 2017
P2, N=778, Recruiting, Sponsor: German Breast Group
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Dec 2018
- || epirubicin / Generic mfg.
Enrollment change: Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies (clinicaltrials.gov) - Feb 23, 2017
P1, N=82, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Dec 2018 N=65 --> 82
- | Trial completion, Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer (clinicaltrials.gov) - Feb 14, 2017
P2/3, N=320, Completed, Sponsor: Chinese Academy of Medical Sciences
N=65 --> 82 Recruiting --> Completed | Phase classification: P3 --> P2/3 | N=500 --> 320 | Initiation date: Jun 2010 --> Jun 2009 | Trial primary completion date: Jun 2020 --> Jan 2016
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Checkpoint inhibition, Checkpoint block: Perioperative Chemo and Pembrolizumab in Gastric Cancer (clinicaltrials.gov) - Jan 31, 2017
P2, N=40, Recruiting, Sponsor: Paul Oberstein
Recruiting --> Completed | Phase classification: P3 --> P2/3 | N=500 --> 320 | Initiation date: Jun 2010 --> Jun 2009 | Trial primary completion date: Jun 2020 --> Jan 2016 Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche
Trial primary completion date, Tumor cell: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (clinicaltrials.gov) - Jan 30, 2017
P2, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2017 --> Oct 2019
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
New P3 trial: Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) (clinicaltrials.gov) - Jan 30, 2017
P3, N=855, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- azacitidine / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: VEOX: Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer (clinicaltrials.gov) - Jan 26, 2017
P1, N=12, Active, not recruiting, Sponsor: Weill Medical College of Cornell University
Trial primary completion date: Sep 2017 --> Oct 2019 Recruiting --> Active, not recruiting | N=16 --> 12 | Trial primary completion date: Jun 2012 --> Aug 2014
- pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Surgery: Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer (clinicaltrials.gov) - Jan 23, 2017
P2, N=60, Recruiting, Sponsor: Rutgers, The State University of New Jersey
Recruiting --> Active, not recruiting | N=16 --> 12 | Trial primary completion date: Jun 2012 --> Aug 2014 Trial primary completion date: Jul 2017 --> Jul 2018
- | New P2 trial, Metastases: CHIMOVIP: Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer (clinicaltrials.gov) - Jan 19, 2017
P2, N=84, Recruiting, Sponsor: Groupe Hospitalier Diaconesses Croix Saint-Simon
- Trial primary completion date: Phase II Trial for Large ER-Negative Breast Cancers (clinicaltrials.gov) - Jan 17, 2017
P2, N=61, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Dec 2016 --> Aug 2017
- pegylated liposomal doxorubicin / Generic mfg., epirubicin / Generic mfg.
New trial: The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Jan 17, 2017
P=N/A, N=270, Recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | epirubicin / Generic mfg.
Enrollment open: Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus (clinicaltrials.gov) - Jan 10, 2017
P3, N=253, Recruiting, Sponsor: Shanghai Zhongshan Hospital
Trial primary completion date: Dec 2016 --> Aug 2017 Not yet recruiting --> Recruiting
- || Ingavirin (imidazolyl ethanamide pentandioic acid) / Myelo Therap, Valenta Pharm
Trial primary completion date: MyeloConcept: Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (clinicaltrials.gov) - Jan 10, 2017
P2a, N=160, Recruiting, Sponsor: Myelo Therapeutics GmbH
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Sep 2017
- Herceptin (trastuzumab) / Roche
Enrollment closed, Enrollment change, Tumor cell: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells (clinicaltrials.gov) - Jan 6, 2017
P2, N=7, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Feb 2017 --> Sep 2017 Recruiting --> Active, not recruiting | N=19 --> 7
- || Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
New P3 trial: TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) - Jan 5, 2017
P3, N=560, Not yet recruiting, Sponsor: Prestige Biopharma Pte Ltd
- || New P3 trial: PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer (clinicaltrials.gov) - Dec 30, 2016
P3, N=320, Recruiting, Sponsor: Shi Yanxia
- | New P4 trial: PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia (clinicaltrials.gov) - Dec 19, 2016
P4, N=240, Recruiting, Sponsor: Shandong Provincial Hospital
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Dec 13, 2016
P2, N=245, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Active, not recruiting | N=19 --> 7 Trial primary completion date: Dec 2012 --> Apr 2011
- | Epidaza (chidamide) / Chipscreen
New P1/2 trial: Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma (clinicaltrials.gov) - Dec 8, 2016
P1/2, N=100, Recruiting, Sponsor: Peking Union Medical College Hospital
- epirubicin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date: Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma (clinicaltrials.gov) - Dec 7, 2016
P2, N=69, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Dec 2012 --> Apr 2011 Trial primary completion date: May 2008 --> Aug 2004
- | epirubicin / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma (clinicaltrials.gov) - Dec 6, 2016
P2, N=69, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: May 2008 --> Aug 2004 Active, not recruiting --> Completed
- | Enrollment closed, Trial primary completion date: PACT-15: Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer (clinicaltrials.gov) - Dec 5, 2016
P2/3, N=370, Active, not recruiting, Sponsor: IRCCS San Raffaele
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Apr 2017
- || New P3 trial: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Dec 2, 2016
P3, N=213, Active, not recruiting, Sponsor: Fudan University
- || epirubicin / Generic mfg.
New P3 trial: Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus (clinicaltrials.gov) - Nov 22, 2016
P3, N=253, Not yet recruiting, Sponsor: Shanghai Zhongshan Hospital
- Trial primary completion date: Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients (clinicaltrials.gov) - Nov 17, 2016
P3, N=2017, Active, not recruiting, Sponsor: Karolinska University Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Apr 2017 Trial primary completion date: Dec 2021 --> Apr 2016
- | Rituxan (rituximab) / Roche
Enrollment change, Trial initiation date: Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Nov 17, 2016
P2/3, N=316, Recruiting, Sponsor: Xinjiang Medical University
Trial primary completion date: Dec 2021 --> Apr 2016 N=200 --> 316 | Initiation date: Sep 2015 --> Sep 2016
- cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
Trial initiation date, Trial primary completion date: The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients (clinicaltrials.gov) - Nov 1, 2016
P2, N=60, Recruiting, Sponsor: Lagos State University
N=200 --> 316 | Initiation date: Sep 2015 --> Sep 2016 Initiation date: Aug 2014 --> Oct 2016 | Trial primary completion date: Jun 2015 --> Oct 2017
- New P2 trial, Surgery: NCT-B4: Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer (clinicaltrials.gov) - Oct 30, 2016
P2, N=40, Not yet recruiting, Sponsor: Jinling Hospital, China
- sorafenib / Generic mfg.
Trial primary completion date, Surgery: Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 11, 2016
P2, N=20, Recruiting, Sponsor: OHSU Knight Cancer Institute
Initiation date: Aug 2014 --> Oct 2016 | Trial primary completion date: Jun 2015 --> Oct 2017 Trial primary completion date: Oct 2016 --> Oct 2017
- Trial primary completion date, Metastases: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Sep 29, 2016
P2/3, N=716, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Aug 2016 --> Dec 2016